Abstract:Chronic hepatitis C virus (HCV) infection exerts its main effects on the liver, promoting hepatic inflammation and fibrosis and increasing the risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma [1]. However, chronic HCV infection also affects organ systems outside of the liver and can contribute to the development of a variety of extrahepatic diseases, most notably atherosclerosis, metabolic alterations (eg, insulin resistance, diabetes mellitus, hepatic steatosis), renal disease (eg, proteinuria, membranoproliferative glomerulonephritis), bone disease (eg, arthralgias, osteoporosis, fractures), neuropsychiatric manifestations (eg, fatigue, cognitive impairment), B-cell non-Hodgkin’s lymphoma, cutaneous disorders (eg, lichen planus, porphyria cutanea tarda), and autoimmune and immune-mediated conditions (eg, mixed cryoglobulinemia, thyroid disease, sicca syndrome) [2, 3]. Some studies have suggested that the incidence of these diseases might be higher for human immunodeficiency virus (HIV)/HCV–coinfected individuals than for those with HCV alone [4, 5]. Regardless of HIV status, HCV-related extrahepatic conditions contribute to morbidity and could increase the risk of nonliver-related mortality [6–9]. The mechanisms for the extrahepatic comorbidities associated with chronic HCV infection are incompletely understood but are likely multifactorial. HCV replication in extrahepatic cells, interactions between HCV proteins and intracellular signaling pathways, HCVinduced stimulation of B-lymphocytes, and immune activation leading to chronic inflammation have all been hypothesized to play a role in the development of these conditions [2, 3]. Lifestyle factors, such as drug and alcohol abuse, smoking, and poor nutrition, may also be important contributors to the development of HCVrelated extrahepatic diseases. There is evidence that successful eradication of chronic HCV infection with interferon-based therapy can ameliorate some extrahepatic complications. Achieving cure of chronic HCV has been associated with improvements in insulin resistance [10–12], reduced risk of diabetes [13], decreased incidence of stroke [14] and lymphoma [15], improvement in neurocognitive function [16], reduction in fatigue [17], and resolution of mixed cryoglobulinemia [18]. These studies were primarily conducted among HIV-uninfected patients, and it remains unclear if HIV differentially affects the impact of cured HCV on specific extrahepatic conditions. Successful treatment of chronic HCV also has been shown to reduce non-liver– related mortality. One cohort study of 530 chronic HCV-infected patients with advanced hepatic fibrosis or cirrhosis found that eradication of chronic HCV with interferon-based treatment significantly reduced rates of all-cause mortality [7], but this study excluded individuals with HIV coinfection. However, a separate cohort study of 1599 HIV/HCV–coinfected patients found that cure of chronic HCV with interferon plus ribavirin was associated with reductions in non-liver– related deaths as well as decreased HIV progression [8]. All-oral direct-acting antiviral (DAA) agents for the treatment of chronic HCV are now available and result in high (≥94%) rates of cure, regardless of HIV status, with minimal adverse effects [19– 22]. Because of their high costs, access to these drugs has been limited in many settings, often only restricted to patients with advanced liver fibrosis or cirrhosis [23–26]. However, if successful treatment of chronic HCV with DAA regimens is shown to improve HCV-related extrahepatic diseases and can reduce nonhepatic morbidity and mortality, including among HIV/HCV–coinfected individuals, then extrahepatic manifestations of chronic HCV may become a major E D I T O R I A L C O M M E N T A R Y

Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation

Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients

Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting

Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010–2018

Direct Antiviral Agents Upregulate Natural Killer Cell Potential Activity in Chronic Hepatitis C Patients

CD4+ T‐cell recovery in HIV/hepatitis C co‐infected patients following successful hepatitis C treatment

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals

Efficacy and Safety of Directly Acting Antiviral Drugs in HCV Patients with HIV in Liver Transplantation: A Meta-Analysis

HCV‐HIV co‐infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece

Efficacy and Safety of Direct Acting Antiviral Regimens for Hepatitis C Virus and Human Immunodeficiency Virus Co‐infection: Systematic Review and Network Meta‐analysis

High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C

Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis

Hepatocellular Carcinoma Decreases the Effectiveness of Hepatitis C Antiviral Treatment: Do Direct‐acting Antiviral Regimens Matter?

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting

DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV

Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters

Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.